MicuRx Pharma, a US-China clinical-stage biopharma, formed a JV with Shanghai Zhangjiang Biomedical Industry Venture Capital. Shanghai Zhangjiang invested 60 million RMB ($9.6 million) in the JV, and MicuRx contributed China rights to its lead antibiotic candidate. MRX-I is a novel, oral oxazolidinone antibiotic that is designed to be effective against antibiotic-resistant infections. MicuRx, which located its China facilities in Zhangjiang Park, will use the money to fund China Phase II and III clinical trials of MRX-I. More details... Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});